Understand the source comparison
Best DSIP Dosage for Insomnia: Protocol Comparison
0.25mg subcutaneous Subcutaneous 90 minutes Minimal effect in Western replication studies; early Soviet trials reported benefit but peptide purity questioned Insufficient dose for most subjects. Trial only if extreme peptide sensitivity suspected 0.5mg subcuta
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- 0.25mg subcutaneous
- Subcutaneous
- 90 minutes
- Minimal effect in Western replication studies; early Soviet trials reported benefit but peptide purity questioned
- Insufficient dose for most subjects. Trial only if extreme peptide sensitivity suspected
- 0.5mg subcutaneous
- 60–90 minutes
- Sleep onset latency reduced by 15–20 minutes; inconsistent slow-wave sleep increase
- Effective starting dose for initial protocol design; escalate if no response after 5–7 days
- 1mg subcutaneous
- Sleep onset latency reduced by 25–30 minutes; SWS duration increased 20–25 minutes
- Standard research dose. Most consistent outcomes across published studies
- 2mg subcutaneous
- SWS duration increased 28–32 minutes; higher probability of vivid dreams and next-morning grogginess
- Reserve for subjects with documented cortisol dysregulation or chronic stress insomnia; marginal benefit over 1mg
- 1mg intranasal
- Intranasal
- 30–60 minutes
- Highly variable absorption; 40–60% inconsistency between subjects
- Not recommended. Subcutaneous delivery far more reliable